The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
PARP1–TDP1 coupling for the repair of topoisomerase I–induced DNA damage
Open accessAbstract
Poly(ADP-ribose) polymerases (PARP) attach poly(ADP-ribose) (PAR) chains to various proteins including themselves and chromatin. Topoisomerase I (Top1) regulates DNA supercoiling and is the target of camptothecin and indenoisoquinoline anticancer drugs, as it forms Top1 cleavage complexes (Top1cc) that are trapped by the drugs. Endogenous and carcinogenic DNA lesions can also trap Top1cc. Tyrosyl-DNA phosphodiesterase 1 (TDP1), a key repair enzyme for trapped Top1cc, hydrolyzes the phosphodiester bond between the DNA 3′-end and the Top1 tyrosyl moiety. Alternative repair pathways for Top1cc involve endonuclease cleavage. However, it is unknown what determines the choice between TDP1 and the endonuclease repair pathways. Here we show that PARP1 plays a critical role in this process. By generating TDP1 and PARP1 double-knockout lymphoma chicken DT40 cells, we demonstrate that TDP1 and PARP1 are epistatic for the repair of Top1cc. The N-terminal domain of TDP1 directly binds the C-terminal domain of PARP1, and TDP1 is PARylated by PARP1. PARylation stabilizes TDP1 together with SUMOylation of TDP1. TDP1 PARylation enhances its recruitment to DNA damage sites without interfering with TDP1 catalytic activity. TDP1–PARP1 complexes, in turn recruit X-ray repair cross-complementing protein 1 (XRCC1). This work identifies PARP1 as a key component driving the repair of trapped Top1cc by TDP1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human CtIP promotes DNA end resection
Sartori, A. A., Lukas, C., Coates, J., Mistrik, M., Fu, S., Bartek, J., Baer, R., Lukas, J., & Jackson, S. P. (2007) · Nature · doi:10.1038/nature06337 · Cited by 1,362 · cited 2×
“Recent studies show that CtIP S322/ / mutant is deficient in interacting with BRCA1 and confers hypersensitivity to CPT (44,53,54).”
BackgroundTakashima, H., Boerkoel, C. F., John, J., Saifi, G. M., Salih, M. A. M., Armstrong, D., Mao, Y., Quiocho, F. A., Roa, B. B., Nakagawa, M., et al. (2002) · Nature Genetics · doi:10.1038/ng987 · Cited by 522
Cited by
The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
Ray Chaudhuri, A., & Nussenzweig, A. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.53 · Cited by 1,786
Roles of eukaryotic topoisomerases in transcription, replication and genomic stability
Pommier, Y., Sun, Y., Huang, S.-Y. N., & Nitiss, J. L. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.111 · Cited by 950
Self-citationLaying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
Pommier, Y., O’Connor, M. J., & de Bono, J. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf9246 · Cited by 739
Self-citationPARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
Rose, M., Burgess, J. T., O’Byrne, K., Richard, D. J., & Bolderson, E. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.564601 · Cited by 719
Human topoisomerases and their roles in genome stability and organization
Pommier, Y., Nussenzweig, A., Takeda, S., & Austin, C. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00452-3 · Cited by 464
Self-citationCristini, A., Groh, M., Kristiansen, M. S., & Gromak, N. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.025 · Cited by 423
Targeting Topoisomerase I in the Era of Precision Medicine
Thomas, A., & Pommier, Y. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1089 · Cited by 337
Self-citationTyrosyl-DNA-phosphodiesterases (TDP1 and TDP2)
Pommier, Y., Huang, S.-Y. N., Gao, R., Das, B. B., Murai, J., & Marchand, C. (2014) · DNA Repair · doi:10.1016/j.dnarep.2014.03.020 · Cited by 336
Self-citationMurai, J., Zhang, Y., Morris, J., Ji, J., Takeda, S., Doroshow, J. H., & Pommier, Y. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.210146 · Cited by 293
Self-citationMechanisms of DNA–protein crosslink repair
Stingele, J., Bellelli, R., & Boulton, S. J. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.56 · Cited by 281
Hopkins, T. A., Shi, Y., Rodriguez, L. E., Solomon, L. R., Donawho, C. K., DiGiammarino, E. L., Panchal, S. C., Wilsbacher, J. L., Gao, W., Olson, A. M., et al. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0191-t · Cited by 270
Coordination of DNA single strand break repair
Abbotts, R., & Wilson, D. M. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.11.039 · Cited by 240
“Additionally, PARP1 physically interacts with the end-processing enzymes tyrosyl-DNA phosphodiesterase 1 (TDP1) and aprataxin (see later), mediating recruitment to damage sites, although not affecting functional activity [100, 101].”
BackgroundTrapping Poly(ADP-Ribose) Polymerase
Shen, Y., Aoyagi-Scharber, M., & Wang, B. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.222448 · Cited by 230
Marzi, L., Szabova, L., Gordon, M., Weaver Ohler, Z., Sharan, S. K., Beshiri, M. L., Etemadi, M., Murai, J., Kelly, K., & Pommier, Y. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0419 · Cited by 60
Self-citationMeisenberg, C., Ashour, M. E., El-Shafie, L., Liao, C., Hodgson, A., Pilborough, A., Khurram, S. A., Downs, J. A., Ward, S. E., & El-Khamisy, S. F. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1026 · Cited by 59
Poly (ADP-ribose) polymerase 1 and neurodegenerative diseases: past, present, and future
Hu, M.-L., Pan, Y.-R., Yong, Y.-Y., Liu, Y., Yu, L., Qin, D.-L., Qiao, G., Law, B. Y.-K., Wu, J.-M., Zhou, X.-G., et al. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102078 · Cited by 44
Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers
Alhusaini, A., Cannon, A., Maher, S. G., Reynolds, J. V., & Lynam-Lennon, N. (2021) · Biomedicines · doi:10.3390/biomedicines9081024 · Cited by 24
Metadata
- Authors
- Das, B. B., Huang, S.-Y. N., Murai, J., Rehman, I., Amé, J.-C., Sengupta, S., Das, S. K., Majumdar, P., Zhang, H., Biard, D., Majumder, H. K., Schreiber, V., & Pommier, Y.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-01-31
- Volume
- 42
- Issue
- 7
- Pages
- 4435-4449
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W2110552264
- Cited by
- 225
- References
- 2
- FWCI
- 7.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.